SBL
TAK icon

Sargent Bickham Lagudis’s Takeda Pharmaceutical TAK Stock Holding History

Sargent Bickham Lagudis’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-739
Closed -$13K – 911
2020
Q3 		$13K Hold
739
– – ﹤0.01% 565
2020
Q2 		$13K Hold
739
– – ﹤0.01% 543
2020
Q1 		$11K Hold
739
– – ﹤0.01% 546
2019
Q4 		$15K Hold
739
– – ﹤0.01% 565
2019
Q3 		$13K Sell
739
-1,201
-62% -$20.8K ﹤0.01% 536
2019
Q2 		$34K Hold
1,940
– – ﹤0.01% 419
2019
Q1 		$40K Buy
+1,940
New +$39K ﹤0.01% 421

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM

Sargent Bickham Lagudis's TAK Position: Q4 2020 in Review

Sargent Bickham Lagudis sold out of Takeda Pharmaceutical (TAK) in Q4 2020, closing a stake of 739 shares — an estimated $13K sold.

Sargent Bickham Lagudis first reported a position in TAK in Q1 2019 and held it in 7 quarters. The position peaked at $40K in Q1 2019. 313 funds tracked by Wall St. Rank hold TAK as of Q4 2020.

  • Sargent Bickham Lagudis reported no remaining Takeda Pharmaceutical position as of Q4 2020 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 739 Takeda Pharmaceutical shares in Q4 2020, an estimated $13K.
  • Sargent Bickham Lagudis first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 7 quarters.
  • Sargent Bickham Lagudis's Takeda Pharmaceutical position peaked at $40K in Q1 2019.
  • 313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2020.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2020, filed 24 May 2021.